Clinical significance of insulin-like growth factor binding proteins (IGFBPs)

Lorraine E. Levitt Katz, Ronald (Ron) Rosenfeld, S. Pinchas Cohen

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The insulin-like growth factors (IGFs) are potent mitogenic agents involved in the regulation of somatic growth and cellular proliferation. Recently, the complex milieu in which they operate has begun to be unraveled. Endocrine and autocrine patterns of IGF secretion have been identified and specific cell surface receptors that bind IGFs and mediate their biological actions have been characterized. The IGF binding proteins (IGFBPs), a family of six peptides that bind IGFs with high affinity (thus regulating IGF availability to its receptors), have been recognized as a new class of growth modulators. The IGFBPs can inhibit IGF actions, enhance the mitogenic effects of IGFs, or function as independent cell regulatory factors, possibly by interacting with their own receptors on the cell membrane. The IGFBPs, in turn, are regulated by the IGFBP proteases, a group of proteolytic enzymes that are capable of cleaving IGFBPs into smaller fragments with lower affinity for the IGFs, thus enhancing IGF action. The six IGFBPs, while similar, have unique biological properties and appear to have specific patterns of expression and function. Radioimmunoassays for IGFBP-1, −2, and −3 are currently commercially available and information is accumulating on their diagnostic usefulness. This includes several clinical situations, such as growth disorders, where serum IGFBP-3 is a highly specific screening tool for growth hormone deficiency, various malignancies in which serum IGFBP-2 levels are elevated, and disorders of carbohydrate metabolism that display an inverse relationship between serum IGFBP-1 and insulin secretion. Current clinical practice may include the judicious use of these tests for the diagnosis and for monitoring the therapeutic response of such disorders.

Original languageEnglish (US)
Pages (from-to)36-43
Number of pages8
JournalEndocrinologist
Volume5
Issue number1
StatePublished - 1995

Fingerprint

Insulin-Like Growth Factor Binding Proteins
Somatomedins
Insulin-Like Growth Factor Binding Protein 2
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Protein 3
Peptide Hydrolases
Serum
Growth Disorders
Carbohydrate Metabolism
Cell Surface Receptors
Growth
Growth Hormone
Radioimmunoassay
Cell Proliferation
Cell Membrane
Insulin
Peptides

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Levitt Katz, L. E., Rosenfeld, R. R., & Cohen, S. P. (1995). Clinical significance of insulin-like growth factor binding proteins (IGFBPs). Endocrinologist, 5(1), 36-43.

Clinical significance of insulin-like growth factor binding proteins (IGFBPs). / Levitt Katz, Lorraine E.; Rosenfeld, Ronald (Ron); Cohen, S. Pinchas.

In: Endocrinologist, Vol. 5, No. 1, 1995, p. 36-43.

Research output: Contribution to journalArticle

Levitt Katz, LE, Rosenfeld, RR & Cohen, SP 1995, 'Clinical significance of insulin-like growth factor binding proteins (IGFBPs)', Endocrinologist, vol. 5, no. 1, pp. 36-43.
Levitt Katz, Lorraine E. ; Rosenfeld, Ronald (Ron) ; Cohen, S. Pinchas. / Clinical significance of insulin-like growth factor binding proteins (IGFBPs). In: Endocrinologist. 1995 ; Vol. 5, No. 1. pp. 36-43.
@article{9673746c06cf4a959338064494739674,
title = "Clinical significance of insulin-like growth factor binding proteins (IGFBPs)",
abstract = "The insulin-like growth factors (IGFs) are potent mitogenic agents involved in the regulation of somatic growth and cellular proliferation. Recently, the complex milieu in which they operate has begun to be unraveled. Endocrine and autocrine patterns of IGF secretion have been identified and specific cell surface receptors that bind IGFs and mediate their biological actions have been characterized. The IGF binding proteins (IGFBPs), a family of six peptides that bind IGFs with high affinity (thus regulating IGF availability to its receptors), have been recognized as a new class of growth modulators. The IGFBPs can inhibit IGF actions, enhance the mitogenic effects of IGFs, or function as independent cell regulatory factors, possibly by interacting with their own receptors on the cell membrane. The IGFBPs, in turn, are regulated by the IGFBP proteases, a group of proteolytic enzymes that are capable of cleaving IGFBPs into smaller fragments with lower affinity for the IGFs, thus enhancing IGF action. The six IGFBPs, while similar, have unique biological properties and appear to have specific patterns of expression and function. Radioimmunoassays for IGFBP-1, −2, and −3 are currently commercially available and information is accumulating on their diagnostic usefulness. This includes several clinical situations, such as growth disorders, where serum IGFBP-3 is a highly specific screening tool for growth hormone deficiency, various malignancies in which serum IGFBP-2 levels are elevated, and disorders of carbohydrate metabolism that display an inverse relationship between serum IGFBP-1 and insulin secretion. Current clinical practice may include the judicious use of these tests for the diagnosis and for monitoring the therapeutic response of such disorders.",
author = "{Levitt Katz}, {Lorraine E.} and Rosenfeld, {Ronald (Ron)} and Cohen, {S. Pinchas}",
year = "1995",
language = "English (US)",
volume = "5",
pages = "36--43",
journal = "Endocrinologist",
issn = "1051-2144",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Clinical significance of insulin-like growth factor binding proteins (IGFBPs)

AU - Levitt Katz, Lorraine E.

AU - Rosenfeld, Ronald (Ron)

AU - Cohen, S. Pinchas

PY - 1995

Y1 - 1995

N2 - The insulin-like growth factors (IGFs) are potent mitogenic agents involved in the regulation of somatic growth and cellular proliferation. Recently, the complex milieu in which they operate has begun to be unraveled. Endocrine and autocrine patterns of IGF secretion have been identified and specific cell surface receptors that bind IGFs and mediate their biological actions have been characterized. The IGF binding proteins (IGFBPs), a family of six peptides that bind IGFs with high affinity (thus regulating IGF availability to its receptors), have been recognized as a new class of growth modulators. The IGFBPs can inhibit IGF actions, enhance the mitogenic effects of IGFs, or function as independent cell regulatory factors, possibly by interacting with their own receptors on the cell membrane. The IGFBPs, in turn, are regulated by the IGFBP proteases, a group of proteolytic enzymes that are capable of cleaving IGFBPs into smaller fragments with lower affinity for the IGFs, thus enhancing IGF action. The six IGFBPs, while similar, have unique biological properties and appear to have specific patterns of expression and function. Radioimmunoassays for IGFBP-1, −2, and −3 are currently commercially available and information is accumulating on their diagnostic usefulness. This includes several clinical situations, such as growth disorders, where serum IGFBP-3 is a highly specific screening tool for growth hormone deficiency, various malignancies in which serum IGFBP-2 levels are elevated, and disorders of carbohydrate metabolism that display an inverse relationship between serum IGFBP-1 and insulin secretion. Current clinical practice may include the judicious use of these tests for the diagnosis and for monitoring the therapeutic response of such disorders.

AB - The insulin-like growth factors (IGFs) are potent mitogenic agents involved in the regulation of somatic growth and cellular proliferation. Recently, the complex milieu in which they operate has begun to be unraveled. Endocrine and autocrine patterns of IGF secretion have been identified and specific cell surface receptors that bind IGFs and mediate their biological actions have been characterized. The IGF binding proteins (IGFBPs), a family of six peptides that bind IGFs with high affinity (thus regulating IGF availability to its receptors), have been recognized as a new class of growth modulators. The IGFBPs can inhibit IGF actions, enhance the mitogenic effects of IGFs, or function as independent cell regulatory factors, possibly by interacting with their own receptors on the cell membrane. The IGFBPs, in turn, are regulated by the IGFBP proteases, a group of proteolytic enzymes that are capable of cleaving IGFBPs into smaller fragments with lower affinity for the IGFs, thus enhancing IGF action. The six IGFBPs, while similar, have unique biological properties and appear to have specific patterns of expression and function. Radioimmunoassays for IGFBP-1, −2, and −3 are currently commercially available and information is accumulating on their diagnostic usefulness. This includes several clinical situations, such as growth disorders, where serum IGFBP-3 is a highly specific screening tool for growth hormone deficiency, various malignancies in which serum IGFBP-2 levels are elevated, and disorders of carbohydrate metabolism that display an inverse relationship between serum IGFBP-1 and insulin secretion. Current clinical practice may include the judicious use of these tests for the diagnosis and for monitoring the therapeutic response of such disorders.

UR - http://www.scopus.com/inward/record.url?scp=0028852842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028852842&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 36

EP - 43

JO - Endocrinologist

JF - Endocrinologist

SN - 1051-2144

IS - 1

ER -